Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer

Data on real-world effectiveness of cyclin-dependent kinase 4/6 inhibitor combination therapy versus endocrine therapy alone are limited. The Flatiron Health Analytic Database was used to assess overall survival (OS) in patients with hormone receptor–positive/human epidermal growth factor receptor 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Rugo, Hope S., Brufsky, Adam, Liu, Xianchen, Li, Benjamin, McRoy, Lynn, Chen, Connie, Layman, Rachel M., Cristofanilli, Massimo, Torres, Mylin A., Curigliano, Giuseppe, Finn, Richard S., DeMichele, Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553912/
https://www.ncbi.nlm.nih.gov/pubmed/36220852
http://dx.doi.org/10.1038/s41523-022-00479-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553912/
https://www.ncbi.nlm.nih.gov/pubmed/36220852
http://dx.doi.org/10.1038/s41523-022-00479-x

Ejemplares similares